The meta‐analytical study constituted the most comprehensive evaluation of cardiotoxicity between concurrent epirubicin–trastuzumab and nonconcurrent regimens to date, comprising 1797 patients with HER2‐positive early breast cancer in seven studies. Here, ERBB2 is linked to breast cancer.